Novavax Inc
Change company Symbol lookup
Select an option...
NVAX Novavax Inc
BBVA Banco Bilbao Vizcaya Argentaria SA
RILY B Riley Financial Inc
WTS Watts Water Technologies Inc
MMM 3M Co
ADTH AdTheorent Holding Company Inc
GAZ iPath? Series B Bloomberg Natural Gas Subindex Total ReturnSM ETN
SNAP Snap Inc
FNB FNB Corp
CNFR Conifer Holdings Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Novavax, Inc., along with its wholly owned subsidiaries, Novavax AB and Novavax CZ, is a biotechnology company. The Company promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).

Closing Price
$11.23
Day's Change
-0.78 (-6.49%)
Bid
--
Ask
--
B/A Size
--
Day's High
12.28
Day's Low
11.18
Volume
(Average)
Volume:
6,466,637

10-day average volume:
7,009,341
6,466,637

Company Profile

Novavax, Inc., along with its wholly owned subsidiaries, Novavax AB and Novavax CZ, is a biotechnology company. The Company promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
0.52x
Price/Book (MRQ)
--
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

January 2023
Current Month
30.9M
Previous Month
30.4M
Percent of Float
36.53%
Days to Cover
3.7836 Days

Share Information

NVAX is in a share class of common stock
Float
84.6M
Shares Outstanding
85.0M
Institutions Holding Shares
363
40.22%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • James Francis Young
  • John C. JacobsPres.
  • James Patrick KellyCFO
  • Gregory M. GlennCorp.Exec.
  • Rick CrowleyCOO

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.